Search results

Evidence-based recommendations on fluocinolone acetonide intravitreal implant (Iluvien) for treating recurrent non-infectious uveitis in adults

Type

Technology appraisal guidance

Published

31 July 2019

Evidence-based recommendations on letermovir (Prevymis) for preventing cytomegalovirus (CMV) disease after a stem cell transplant in adults

Type

Technology appraisal guidance

Published

31 July 2019

Evidence-based recommendations on nusinersen (Spinraza) for treating spinal muscular atrophy in children and adults

Type

Technology appraisal guidance

Published

24 July 2019

Evidence-based recommendations on blinatumomab (Blincyto) for treating Philadelphia-chromosome-negative CD19-positive B-precursor acute lymphoblastic leukaemia

Type

Technology appraisal guidance

Published

24 July 2019

Evidence-based recommendations on enzyme-linked immunosorbent assay (ELISA) tests for therapeutic monitoring of tumour necrosis factor (TNF)-alpha inhibitors in

Type

Diagnostics guidance

Published

10 July 2019

Evidence-based recommendations on the bisphosphonates alendronic acid, ibandronic acid, risedronate sodium and zoledronic acid for treating osteoporosis

Type

Technology appraisal guidance

Last updated

08 July 2019

Evidence-based recommendations on lenalidomide (Revlimid) for treating multiple myeloma in adults who have had at least 2 prior therapies

Type

Technology appraisal guidance

Last updated

26 June 2019

Evidence-based recommendations on lenalidomide (Revlimid) for myelodysplastic syndromes associated with an isolated deletion 5q cytogenetic abnormality

Type

Technology appraisal guidance

Last updated

26 June 2019

Evidence-based recommendations on lenalidomide (Revlimid) plus dexamethasone for multiple myeloma after 1 treatment with bortezomib in adults

Type

Technology appraisal guidance

Published

26 June 2019

Evidence-based recommendations on lenalidomide (Revlimid) plus dexamethasone for previously untreated multiple myeloma in adults

Type

Technology appraisal guidance

Published

26 June 2019

Evidence-based recommendations on ocrelizumab (Ocrevus) for treating primary progressive multiple sclerosis (MS) in adults

Type

Technology appraisal guidance

Published

12 June 2019

Evidence-based recommendations on atezolizumab (Tecentriq) with bevacizumab (Avastin), carboplatin and paclitaxel for metastatic non-squamous non-small-cell

Type

Technology appraisal guidance

Published

05 June 2019

Evidence-based recommendations on ertugliflozin (Steglatro) with metformin and a dipeptidyl peptidase-4 inhibitor for type 2 diabetes in adults

Type

Technology appraisal guidance

Published

05 June 2019

NICE is unable to make a recommendation about the use in the NHS of cabozantinib (Cometriq) for previously treated advanced hepatocellular carcinoma in adults

Type

Technology appraisal guidance

Published

24 May 2019

Evidence-based recommendations on inotersen (Tegsedi) for stage 1 and stage 2 polyneuropathy in adults with hereditary transthyretin amyloidosis

Type

Highly specialised technologies guidance

Published

22 May 2019

Evidence-based recommendations on enzalutamide (Xtandi) for treating high-risk hormone-relapsed non-metastatic prostate cancer in adults

Type

Technology appraisal guidance

Published

15 May 2019

Evidence-based recommendations on nivolumab (Opdivo) with ipilimumab (Yervoy) for untreated advanced renal cell carcinoma that is intermediate- or poor-risk in

Type

Technology appraisal guidance

Published

15 May 2019

Evidence-based recommendations on lead-I electrocardiogram (ECG) devices (imPulse, Kardia Mobile, MyDiagnostick and Zenicor-ECG) for detecting symptomatic

Type

Diagnostics guidance

Published

08 May 2019

Evidence-based recommendations on abemaciclib (Verzenios) for treating hormone receptor-positive, HER2-negative locally advanced or metastatic breast cancer

Type

Technology appraisal guidance

Published

08 May 2019

Evidence-based recommendations on durvalumab (Imfinzi) for treating locally advanced unresectable non-small-cell lung cancer after platinum-based chemoradiation

Type

Technology appraisal guidance

Published

01 May 2019

Evidence-based recommendations on brentuximab vedotin (Adcetris) for treating CD30-positive cutaneous T-cell lymphoma in adults

Type

Technology appraisal guidance

Published

24 April 2019

Evidence-based recommendations on certolizumab pegol (Cimzia) for treating moderate to severe plaque psoriasis in adults

Type

Technology appraisal guidance

Published

17 April 2019

Evidence-based recommendations on tildrakizumab (Ilumetri) for treating moderate to severe plaque psoriasis in adults

Type

Technology appraisal guidance

Published

17 April 2019

NICE is unable to make a recommendation about the use in the NHS of bosutinib for untreated chronic myeloid leukaemia because no evidence submission was

Type

Technology appraisal guidance

Published

17 April 2019

Evidence-based recommendations on daratumumab (Darzalex) with bortezomib and dexamethasone for previously treated multiple myeloma in adults

Type

Technology appraisal guidance

Published

10 April 2019

Evidence-based recommendations on ertugliflozin (Steglatro) as monotherapy or with metformin for treating type 2 diabetes in adults

Type

Technology appraisal guidance

Published

27 March 2019

NICE is unable to make a recommendation about the use in the NHS of pembrolizumab (Keytruda) for treating recurrent or metastatic squamous cell carcinoma of the

Type

Technology appraisal guidance

Published

20 March 2019

Evidence-based recommendations on brigatinib (Alunbrig) for treating anaplastic lymphoma kinase (ALK)-positive advanced non-small-cell lung cancer in adults who

Type

Technology appraisal guidance

Published

20 March 2019

Evidence-based recommendations on pertuzumab (Perjeta) for adjuvant treatment of HER2-positive early stage breast cancer in adults

Type

Technology appraisal guidance

Published

20 March 2019

Evidence-based recommendations on tisagenlecleucel therapy (Kymriah) for treating relapsed or refractory diffuse large B-cell lymphoma in adults after 2 or more

Type

Technology appraisal guidance

Published

13 March 2019

NICE is unable to make a recommendation on abatacept (Orencia) for treating psoriatic arthritis after DMARDs in adults because of no evidence submission from

Type

Technology appraisal guidance

Published

13 March 2019

Evidence-based recommendations on cochlear implants for children and adults with severe to profound deafness

Type

Technology appraisal guidance

Published

07 March 2019

NICE is unable to make a recommendation about the use in the NHS of dabrafenib with trametinib for treating advanced metastatic BRAF V600E mutation-positive

Type

Technology appraisal guidance

Published

27 February 2019

Evidence-based recommendations on venetoclax (Venclyxto) with rituximab for previously treated chronic lymphocytic leukaemia in adults

Type

Technology appraisal guidance

Published

27 February 2019

Evidence-based recommendations on encorafenib (Braftovi) with binimetinib (Mektovi) for treating unresectable or metastatic BRAF V600 mutation-positive melanoma

Type

Technology appraisal guidance

Published

27 February 2019

Evidence-based recommendations on abemaciclib (Verzenios) for treating locally advanced or metastatic, hormone receptor-positive, human epidermal growth factor

Type

Technology appraisal guidance

Published

27 February 2019

NICE is unable to make a recommendation about the use in the NHS of bevacizumab with carboplatin, gemcitabine and paclitaxel for treating the first recurrence

Type

Technology appraisal guidance

Published

20 February 2019

This guideline sets out an antimicrobial prescribing strategy for acute cough associated with an upper respiratory tract infection or acute bronchitis in adults, young people and children. It aims to limit antibiotic use and reduce antibiotic resistance.

Type

Antimicrobial prescribing guideline

Published

07 February 2019

Evidence-based recommendations on nivolumab (Opdivo) for adjuvant treatment of completely resected melanoma with lymph node involvement or metastatic disease

Type

Technology appraisal guidance

Published

23 January 2019

Evidence-based recommendations on axicabtagene ciloleucel therapy (Yescarta) for treating diffuse large B-cell lymphoma and primary mediastinal B-cell lymphoma

Type

Technology appraisal guidance

Published

23 January 2019

Evidence-based recommendations on pembrolizumab (Keytruda) with pemetrexed and platinum chemotherapy for untreated, metastatic, non-squamous non-small-cell lung

Type

Technology appraisal guidance

Published

10 January 2019

Evidence-based recommendations on regorafenib (Stivarga) for treating advanced hepatocellular carcinoma (liver cancer) in adults who have had sorafenib

Type

Technology appraisal guidance

Published

09 January 2019

Evidence-based recommendations on darvadstrocel (Alofisel; stem-cell treatment) for complex perianal fistulas with mildly or non-active luminal Crohn’s disease

Type

Technology appraisal guidance

Published

09 January 2019

Evidence-based recommendations on tisagenlecleucel therapy (Kymriah) for treating relapsed or refractory B-cell acute lymphoblastic leukaemia in people aged up

Type

Technology appraisal guidance

Published

21 December 2018

Evidence-based recommendations on tumour profiling tests to guide adjuvant chemotherapy decisions for people with early breast cancer. The tests are EndoPredict

Type

Diagnostics guidance

Published

19 December 2018

Evidence-based recommendations on lenvatinib (Lenvima) for untreated advanced hepatocellular carcinoma (HCC) in adults

Type

Technology appraisal guidance

Published

19 December 2018

Evidence-based recommendations on liposomal cytarabine–daunorubicin (Vyxeos) for untreated acute myeloid leukaemia (AML) in adults

Type

Technology appraisal guidance

Published

19 December 2018

Evidence-based recommendations on pembrolizumab (Keytruda) for adjuvant treatment of stage III melanoma with lymph node involvement in adults

Type

Technology appraisal guidance

Published

19 December 2018

This guideline sets out an antimicrobial prescribing strategy for managing and preventing acute exacerbations of bronchiectasis (non-cystic fibrosis). It aims to optimise antibiotic use and reduce antibiotic resistance.

Type

Antimicrobial prescribing guideline

Published

18 December 2018

Evidence-based recommendations on vandetanib (Caprelsa) for treating medullary thyroid cancer in adults

Type

Technology appraisal guidance

Published

12 December 2018